RNATICS'
pipeline
The unique macrophage-targeted delivery technology provides tremendous opportunity. Hence, RNATICS develops RNA therapeutics for a variety of inflammatory and fibrotic diseases with high unmet medical need.
Indications
The first indication for RNATICS’ most advanced drug candidate, RCS-21, will be acute exacerbations in patients suffering from Idiopathic Pulmonary Fibrosis (IPF). RCS-21 specifically inhibits microRNA-21, which is among the strongest upregulated microRNAs in alveolar macrophages of individuals suffering from severe inflammation. Targeted inhibition of miR-21 has shown significant reduction of pulmonary inflammation, amelioration of lung damage elicited by scarring, and marked improvement of lung function in a therapeutic proof-of-concept study in a preclinical animal model of inflammatory lung damage.
Further inflammatory and fibrotic diseases of the lung are currently under investigation.
Clinical Development
Formal safety and toxicology studies have been concluded and confirmed the non-hazardous nature of the lead compound RCS-21, it was well tolerated at the dose groups tested. The Federal Institute for Drugs and Medical Devices (BfArM) has already approved the conduct of the Phase 1 clincal trial in healthy volunteers. The first dosing is planned in Q1 2025.